Capricor’s Deramiocel Briefing Is a Masterclass in How Not to Define an Endpoint

The FDA released its briefing document for Capricor Therapeutics’ Deramiocel (BLA 125842) on July 27, 2026, one day before this column publishes and two days before the Cellular, Tissue, and Gene Therapies Advisory Committee convenes on July 29. The agency’s conclusion is unambiguous: the evidence does not demonstrate efficacy. Capricor, meanwhile, announced in December 2025 that its pivotal Phase 3 HOPE-3 study met its primary endpoint across 106 participants at 20 U.S. clinical sites. Two parties reviewed the same data package. They reached opposite conclusions. The question the AdCom will try to answer tomorrow is really a different one: how does a sponsor walk into a BLA believing it has proven efficacy when the FDA’s own reviewers say it has not?

That gap between sponsor conviction and agency skepticism rarely appears from nowhere. It is built, brick by brick, over years of protocol decisions, endpoint selections, and pre-submission meetings where difficult conversations were deferred rather than resolved.

The Endpoint at the Center of the Dispute

Deramiocel is an allogeneic cardiosphere-derived cell therapy targeting cardiomyopathy in DMD patients. The cardiac manifestation of DMD is eventually fatal, and there are no approved therapies specifically for DMD-associated cardiomyopathy. That unmet need is real and urgent. But unmet need has never substituted for a well-constructed efficacy demonstration, and the FDA briefing document for BLA 125842 makes clear the agency does not believe Capricor delivered one.

The HOPE-3 trial enrolled 106 DMD participants in a randomized, double-blind, placebo-controlled design. On its face, that is a credible pivotal structure. But the primary endpoint definition, and what Capricor chose to treat as confirmatory evidence of efficacy, is where the regulatory case collapses. The FDA’s own guidance on dystrophinopathies, published on the agency’s website, acknowledges that there is “no defined set of required or recommended clinical outcome measures for studies in dystrophinopathies.” That ambiguity is not a gift to sponsors. It is a test of rigor. A sponsor without a mandated endpoint must build a more compelling case, not a more convenient one.

Capricor apparently read the ambiguity differently.

The six-minute walk test has been a workhorse in DMD trial programs, but it measures ambulatory function, not cardiac performance. Research published through Washington University’s clinical network, drawing on 174 ambulatory males with nonsense-mutation DMD, confirmed the 6MWT’s feasibility and reliability in multicenter settings, but feasibility and reliability are properties of a measurement instrument. They do not automatically confer appropriateness for a cardiac-specific indication. If Capricor anchored its efficacy story on functional endpoints that the FDA considered insufficient to characterize cardiomyopathy benefit, the briefing document outcome was predictable long before December 2025.

A Regulatory History That Should Have Flashed Red

This is not the first time Capricor has stood at this intersection with FDA. The company’s regulatory history with Deramiocel includes an initial BLA submission, a rejection, and a resubmission before the current review cycle. That sequence matters. A Complete Response Letter is not a bureaucratic speed bump. It is the FDA telling a sponsor, in formal writing, that the evidentiary package has failed to meet the approval standard. When a sponsor resubmits after a CRL, the agency expects to see a fundamentally different or materially strengthened dataset. The fact that FDA reviewers are still expressing efficacy concerns after resubmission suggests Capricor did not solve the underlying evidentiary problem. It may have repackaged it.

The Pre-BLA meeting timeline adds another layer. Capricor announced its Pre-BLA meeting in the third quarter of 2024 and filed its BLA in October 2024. That is a compressed runway from a pre-submission alignment conversation to a formal application on a program with known endpoint complexity and a prior rejection on its record. Pre-BLA meetings are the moment when a sponsor can surface exactly the kind of endpoint interpretation disagreement that is now playing out in a public briefing document. If the FDA signaled concerns about efficacy characterization at that meeting and Capricor filed anyway, that is a strategic calculation that backfired catastrophically. If the FDA did not signal those concerns clearly, that is a different accountability problem, and it belongs to the agency.

The DMD space has seen this pattern before. Sarepta Therapeutics’ exon-skipping programs, including Exondys 51 (eteplirsen) and Vyondys 53 (golodirsen), both received accelerated approval on the basis of dystrophin production as a surrogate endpoint reasonably likely to predict clinical benefit, not demonstrated motor or functional improvement. The FDA accepted a biomarker rationale because the mechanistic link to clinical benefit was scientifically defensible. Capricor’s challenge is that cardiosphere-derived cell therapy in DMD cardiomyopathy requires a different kind of proof: direct cardiac functional improvement in a population that is simultaneously experiencing systemic neuromuscular progression. Designing an endpoint that isolates cardiac benefit from that background noise is genuinely hard. The briefing document suggests Capricor did not meet that challenge.

What Sponsors Running Rare Disease Trials Must Confront

The structural read here is uncomfortable for the entire rare disease development community, not just Capricor. When the FDA acknowledges it has no defined endpoint requirements for a disease area, sponsors face a choice between two approaches. The first is conservative: run the hardest possible trial with the most clinically meaningful endpoint, accept a longer timeline and higher cost, and arrive at the BLA with an unassailable evidentiary record. The second is optimistic: interpret the absence of defined requirements as flexibility, select endpoints that are achievable given the patient population and disease progression, and argue for their clinical relevance in the submission. Capricor appears to have taken the second path. The briefing document represents the FDA’s rejection of that interpretation.

That dynamic is not unique to DMD. Across rare disease programs with small patient populations and no established endpoints, sponsors routinely face the temptation to design trials around what is measurable rather than what is meaningful. With only 106 participants in HOPE-3, Capricor had limited statistical power to run multiple confirmatory analyses. That constraint is real. But the answer to a power problem is a more targeted and pre-specified primary endpoint with a clearly defined minimal clinically important difference, not a primary endpoint whose clinical significance the FDA then disputes in a public briefing document the day before an advisory committee vote.

For sponsors watching tomorrow’s AdCom, the operational directive is specific: every endpoint selection decision in a rare disease program should be accompanied by a written FDA alignment memo from the most recent Type B meeting, with explicit language about whether the agency considers that endpoint sufficient to support approval. “No objection” language in a meeting summary is not alignment. A written statement that the primary endpoint, if met at the pre-specified threshold, would constitute substantial evidence of effectiveness is alignment. Anything short of that is a gap Capricor has now demonstrated can swallow an entire program.

For site directors who enrolled patients in HOPE-3 across those 20 U.S. sites: 106 DMD participants and their families participated in a double-blind trial on the basis that a positive result could reach approval. The briefing document, if it translates into a negative AdCom vote tomorrow, will mean those patients and families get a negative answer to a question that the sponsor may not have framed precisely enough to answer in the first place. That accountability does not appear in any 483 observation. It belongs in this column.

The July 29 AdCom vote is the next signal. Watch not just the tally but the panel’s specific language around endpoint adequacy. If committee members cite the absence of a cardiac-specific primary endpoint as the dispositive deficiency, Capricor’s path to resubmission narrows considerably. A third attempt will require either new clinical data or a fundamental redesign of the evidentiary strategy, and neither comes quickly in a disease where patients are running out of time.

References

1. Endpoints News — “Capricor’s DMD therapy lacks efficacy, FDA says ahead of adcomm”
2. Capricor Therapeutics — “Capricor Therapeutics Announces Positive Topline Results from HOPE-3 Phase 3 Study of Deramiocel in DMD” (December 3, 2025)
3. AllSci — “FDA Briefing Casts Doubt on Capricor’s Deramiocel Ahead of DMD Advisory Committee” (July 27, 2026)
4. FDA — Guidance for Industry: Duchenne Muscular Dystrophy and Related Dystrophinopathies
5. Washington University — “The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study”
6. Molina Healthcare — Vyondys 53 (golodirsen) Clinical Policy: FDA Accelerated Approval Basis
7. NeurologyLive — “Capricor DMD Cardiomyopathy Cell Therapy Deramiocel Back Under Review at FDA”
8. Capricor Therapeutics — “Capricor Therapeutics Announces Pre-BLA Meeting with FDA” (Q3 2024)